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Abstract
The last step of cysteine biosynthesis in bacteria and plants is catalyzed by O-acetylserine sulfhydrylase. In bacteria, two
isozymes, O-acetylserine sulfhydrylase-A and O-acetylserine sulfhydrylase-B, have been identified that share similar binding
sites, although the respective specific functions are still debated. O-acetylserine sulfhydrylase plays a key role in the
adaptation of bacteria to the host environment, in the defense mechanisms to oxidative stress and in antibiotic resistance.
Because mammals synthesize cysteine from methionine and lack O-acetylserine sulfhydrylase, the enzyme is a potential
target for antimicrobials. With this aim, we first identified potential inhibitors of the two isozymes via a ligand- and
structure-based in silico screening of a subset of the ZINC library using FLAP. The binding affinities of the most promising
candidates were measured in vitro on purified O-acetylserine sulfhydrylase-A and O-acetylserine sulfhydrylase-B from
Salmonella typhimurium by a direct method that exploits the change in the cofactor fluorescence. Two molecules were
identified with dissociation constants of 3.7 and 33 mM for O-acetylserine sulfhydrylase-A and O-acetylserine sulfhydrylase-B,
respectively. Because GRID analysis of the two isoenzymes indicates the presence of a few common pharmacophoric
features, cross binding titrations were carried out. It was found that the best binder for O-acetylserine sulfhydrylase-B
exhibits a dissociation constant of 29 mM for O-acetylserine sulfhydrylase-A, thus displaying a limited selectivity, whereas the
best binder for O-acetylserine sulfhydrylase-A exhibits a dissociation constant of 50 mM for O-acetylserine sulfhydrylase-B
and is thus 8-fold selective towards the former isozyme. Therefore, isoform-specific and isoform-independent ligands allow
to either selectively target the isozyme that predominantly supports bacteria during infection and long-term survival or to
completely block bacterial cysteine biosynthesis.
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enzymes involved in sulfur metabolism, and specifically in cysteine
biosynthesis, are targets for the development of novel antibiotics
[4,6,10–23]. For example, S. typhimurium knock-out for cysteine
synthase showed an increased susceptibility to ciprofloxacin, with a
MIC 500-fold lower than wild type bacterium [24]. The
mechanism of action of antimonials in the treatment of
Leishmaniasis has been demonstrated to be linked to the
biosynthesis of trypanothione and to a marked decrease in cellular
thiol redox potential [25]. Furthermore, inactivation of enzymes
involved in cysteine and methionine biosynthesis in Mycobacterium
tuberculosis, significantly reduces bacterial virulence and persistence
during the chronic phase of infection in mice [22]. Therapeutic
strategies against microbes that rely heavily on sulphur metabolism
for efficient host infection and colonization, such as M. tuberculosis
and Entamoeba histolytica, have been proposed [4,11].

Introduction
In bacteria and plants cysteine is the only source of sulfur that is
required for the synthesis of a variety of biomolecules, including
methionine, Fe-S clusters, thiamine, glutathione, and biotin [1,2].
In microorganisms, cysteine supplies the reducing power for
protection against oxidative stress, either directly [3] or indirectly
via reducing systems like glutathione/glutathione reductase,
mycothione/mycothione reductase [4] or trypanothione/trypanotathione reductase [5]. In bacteria, cysteine is synthesized via the
reductive sulfate assimilation pathway involving five enzymes
(Figure 1). The cysteine regulon of pathogenic microorganisms is
up-regulated, in vitro, under oxidative stress [6], in the presence of
nitric oxide [7], and in vivo, during infection or long term survival
[8,9]. It has been proposed and experimentally proved that

PLOS ONE | www.plosone.org

1

October 2013 | Volume 8 | Issue 10 | e77558

O-acetylserine sulfhydrylase Ligands

Figure 1. Cysteine biosynthesis. Upper panel: Intermediates of cysteine biosynthesis in mammals and bacteria. The red arrows indicate the
biosynthetic pathway in mammals and the yellow arrows the biosynthetic pathway in bacteria. Lower panel: Sulfur assimilation in bacteria. Sulfate
and thiosulfate are the most abundant forms of extracellular sulfur, the latter being predominant under less oxidizing conditions. Inorganic sulfur
enters the cells through specific transporters. In contrast to OASS-A, OASS-B can directly use thiosulfate for cysteine biosynthesis. The product S-sulfoL-cysteine is reduced by glutaredoxins to cysteine and sulfide that enters in the last step of the sulfate reduction pathway [120,121].
doi:10.1371/journal.pone.0077558.g001

The catalytic mechanism [27,28], spectroscopic properties [29–
32], and stability [33–35] of OASS-A have been characterized and
compared with those of OASS-B [36]. The enzyme belongs to the
fold type II of the PLP-dependent enzyme family [37], whose
prototype is tryptophan synthase [38,39]. The three-dimensional
structure of OASS from different species was determined,
including Haemophilus influenzae, Escherichia coli, S. typhimurium, E.
histolitica, Aeropyrum pernix, Thermotoga maritima, M. tuberculosis,
Leishmania major and Arabidopsis thaliana, either in the absence or
presence of ligands [16,36,40–54].

In most bacteria and plants, cysteine biosynthesis culminates
with the b-replacement of an activated serine derivative, Oacetylserine, by bisulfide, catalyzed by a family of enzymes known
as O-acetylserine sulfhydrylases (OASS) [26]. OASS is a member
of the cysteine synthase superfamiliy [26] and is a pyridoxal 59phosphate-dependent enzyme. Two OASS isozymes, OASS-A
and OASS-B, have been identified that are differentially expressed
depending on growth conditions. OASS-A is present at basal levels
and is favored under aerobic conditions and in rich media,
whereas OASS-B is expressed under anaerobic conditions [27].
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2JC3 [36], respectively). Structures were checked for chemically
consistent atom and bond type assignments using the molecular
modeling program Sybyl 8.1 (www.tripos.com). Amino-terminal
and carboxy-terminal groups were set as protonated and
deprotonated, respectively. The PLP atoms were renamed
according to the GRID library (grub.dat) to allow the program
to properly recognize the cofactor. Hydrogen atoms were
computationally added using Sybyl Biopolymer and Build/Edit
menu tools and energy-minimized using the Powell algorithm,
with a convergence gradient # 0.5 kcal (mol s)21 and a
maximum of 1500 cycles.
The Specs database (www.specs.net) was chosen as starting
library for performing virtual screening simulations. This database
is part of the ZINC archive [68] (www.zinc.docking.org) and,
according to previous experiences [89,93,98], contains molecules
with significant chemical and geometric diversity, good purity and
availability. A set of about 300,000 compounds was downloaded
and filtered according to their LogP values calculated by Moka
[99–101]. In order to assure sufficient solubility, only molecules
with LogP # 1 were retained, amounting, in this experiment, to
11,937. The pharmacophoric analysis and the virtual screening
were performed with FLAP (Fingerprints for Ligands and Proteins)
software [69], developed and licensed by Molecular Discovery
Ltd. (www.moldiscovery.com). FLAP is based on the Molecular
Interaction Fields (MIFs) calculated by GRID [102], used to
describe small molecules and protein structures in terms of 4-point
pharmacophoric fingerprints. FLAP MIFs provide a very accurate
and efficiently compressed description of 3D molecular features
and interactions modeled on the base of GRID MIFs. The
fingerprint makes the method extremely fast, and is used for pose
prediction and GRID MIFs similarity calculation, thus allowing to
evaluate the complementarities of the ligands to the receptor. The
algorithm calculates the GRID-MIFs for the template molecule
derived from ligands (Ligand-Based Virtual Screening, LBVS) or
from the pharmacophoric image of the binding site (StructureBased Virtual Screening, SBVS) and for the screened compounds.
The hotspots are combined in quadruplets (the-4 points). The
quadruplets of each molecule contained in the database are
compared with the quadruplets of the template. Matching
quadruplets are used to overlay the compounds 3D-structure onto
the template and, as determined by overlapping of the MIFs, the
similarity is assigned to generate a 3D pharmacophoric hypothesis
[69]. MIF similarity scores can be referenced to the best alignment
obtained with a single probe, when the product of two or more
probes is used. The ligand orientations simultaneously represent
the best MIF alignment for a given probe. The FLAP approach
has been successfully applied in several virtual screening analyses
[88–97]. This procedure allows the quick removal of molecules
with a low probability of interacting with the target and, thereby,
selects the most interesting candidates with chemical and structural
complementarities with the receptor binding site and/or its known
ligands.
Before starting any virtual screening analysis, the molecules
were minimized with the ‘‘mizer’’ module. Once screening was
completed, the compounds from SBVS and LBVS were ranked
according to the Global Sum score of FLAP and the distance to
the model (FLAP distance score) [103]. In the perspective of a
consensus scoring approach, the most promising candidates were
docked into the binding pocket of the respective targets with
GOLD, version 3.1 (www.ccd.cam.ac.uk), and then rescored with
HINT [72]. For each compound, 50 diverse poses were generated
and analyzed. A radius of 15 Å was used to direct site location. A
maximum number of 100,000 operations were performed for each
docking search, on a population of 100 individuals with a selection

The interaction of OASS with serine acetyltransferase (SAT),
the preceding enzyme in the cysteine biosynthetic pathway, has
been characterized determining both the binding affinity and
kinetic mechanism [16,55–63]. OASS-A forms a tight complex
with SAT with a Kd in the nanomolar range [55,61], whereas
OASS-B does not interact with SAT [55,56]. SAT binds to the
OASS-A active site via its C-terminal peptide, resulting in a
competitive inhibition of OASS [45,61]. OASS-A forms a fast
encounter complex with SAT, followed by a slow conformational
change [64]. The structure of OASS-A from H. influenzae was
determined with the C-terminal decapeptide of SAT bound in the
active site [45]. Only the last four amino acids (NLNI) were
detected, suggesting that they have a specific role in the energetics
of the interaction. This conclusion is supported by extensive
mutational and computational analysis [16,61], also showing the
relevance of the C-terminal amino acid isoleucine for OASS-SAT
formation [51,65]. The contribution of individual amino acids
contained in the C-terminal sequence of SAT to complex
formation and to binding specificity towards OASS-A and
OASS-B was investigated using a small library of pentapeptides
[19,66]. Furthermore, recently, inhibitors for OASS-A have been
obtained via a classical medicinal chemistry approach [18] and by
virtual screening [11,67].
For the identification of ligands specific for either OASS-A or
OASS-B from S. thyphimurium we carried out complementary in
silico and in vitro investigations. Our approach is based on the in
silico screening of a subset of the ZINC library [68] with FLAP
[69], docking with GOLD [70,71] and re-scoring using HINT
[72]. Many different approaches are exploited for in silico
screening. As stated by Ma et al. [73] structure- or ligand-based
virtual screening methods, usually based on fingerprinting, are
used for simulating the interactions of a biomolecular target with
compounds libraries in a rapid and cost-effective manner. FLAP
belongs to this category of fingerprint methods, normally classified
according to their dimensionality ranging from 1D to 3D [74].
The main strength of these approaches lies in their ability of
comparing multiple fingerprints, i.e. a mathematical representation of a molecule, and computing their similarity using similarity
coefficients [75]. Given the increased availability of computer
power, docking approaches have been also exploited for screening
and for investigating the binding mode of small molecules into the
target binding pocket. Docking methods that have been developed
and successfully applied in virtual screening experiments include
AutoDock and AutoDock Vina [76–78]; DOCK [79–81]; FlexX
[82]; Glide [83]; GOLD [84,85]; Surflex [86,87]. Their strengths
and weaknesses, along with applications, have been reported by
Bielska et al. [75]. Our choice of using FLAP was based on the
available computational resource and on the positive results
previously obtained [88–97].
The binding affinities of the best hits were evaluated in vitro on
purified OASS-A and OASS-B, exploiting the change of PLP
fluorescence emission upon binding [30–32,55]. Ligands that bind
to either OASS-A or OASS-B with Kd of 4–34 mM were
identified. As a somewhat serendipitous result, ligands that bind
to both isoforms with Kds in the micromolar range were also
found. This result is fully explained by a few common
pharmacophoric features of the active site, in spite of the
completely distinct ability of interaction with SAT.

Materials and Methods
Virtual Screening
OASS-A and OASS-B structures from S. typhimurium were
retrieved from the PDB database (PDB codes 1OAS [47] and
PLOS ONE | www.plosone.org
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Figure 2. Structural comparison of OASS-A and OASS-B. Panel A: Structure-based amino acid sequence alignment of OASS-A and OASS-B
from Salmonella typhimurium. The alignment, carried out on the PDB entries 1OAS and 2JC3 using the Flexible structure AlignmenT (FATCAT) method
[122], gave an overall identity of 40.32% and a similarity of 56.51%. Identical residues have a red background and residues with similar
physicochemical properties are shown in red. Similarity scores were calculated by the ESPript program [123] using the Blosum62 matrix set at global
score of 0.2. Residues of the first active site shell are indicated by dark circles below the alignment. Panel B: Active site of OASS-A. Residues of the
first active site shell and PLP are shown in ball and stick style, colored pink and yellow, respectively. Panel C: Active site of OASS-B. Residues of the
first active site shell and PLP are shown in ball and stick style, colored cyan and yellow, respectively.
doi:10.1371/journal.pone.0077558.g002

atom-atom interaction contributions that is proportional to the
free energy of binding, as previously described [16,104].
All calculations were run on a 8 CPU workstation Intel(R)
Xeon(R) CPU X5560 @ 2.80 GHz, with a 16 GB 1333 MHz
RAM, and a Linux operating system RHEL 5.4 x86_64, kernel
version 2.6.18–164.el5. Given the available computational resource, and good results previously obtained, the FLAP software
represented to us the best choice for performing rapid and
profitable virtual screening analysis. The application of other

pressure of 1.1. Operator weights for crossover, mutation, and
migration were set to 95, 95 and 10, respectively. The number of
islands and the niche were set to 5 and 2. No constraints were
imposed. Polar hydrogen atoms in the binding pocket were
optimized for hydrogen bonding during docking simulations. The
default GOLDScore fitness was used as native scoring function
[71]. HINT was then used as post-docking processor scoring
function [104–108]. The HINT score provides a quantitative
evaluation of ligand-protein interaction as a sum of all individual
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Figure 3. LigPlot of the wild type tetrapeptide ligand in the active site of Haemophilus influenzae OASS. The interactions between the
Asn-Leu-Asn-Ile tetrapeptide and the active site residues of H. influenzae OASS-A (PDB code: 1Y7L) are reported. The figure was drawn with LigPlot
program version 4.5.3 [124].
doi:10.1371/journal.pone.0077558.g003

where I is the fluorescence intensity at 500 nm in the presence of
the ligand, I0 is the fluorescence intensity in the absence of ligand,
Imax is the maximum fluorescence change at saturating ligand
concentrations, [L] is the ligand concentration, and Kd is the
dissociation constant of the OASS-ligand complex. This measurement is a direct determination of ligand dissociation constant in
the absence of substrate, thus it coincides with Ki, independently
from the inhibition mechanism.

methods, such as docking, might result in the identification of
different compounds, given their powerful search in the conformational space [75].

Chemicals
Chemicals, purchased from Sigma-Aldrich, were of the best
available quality and used as received. Experiments, if not
otherwise indicated, were carried out in 100 mM Hepes buffer,
pH 7.0, at 20 uC.

Results and Discussion
Determination of ligand binding affinity to OASS-A and
OASS-B

The biochemical investigation of OASS-A and OASS-B
reactivity [36] and active site specificity probed by pentapeptides
[19] indicate that, despite an overall 40% sequence identity and a
70% sequence identity for the first active site shell (Figure 2A), the
two isozymes exhibit subtle but significant structural differences
(Figure 2B,C). Most of the residues of the first active site shell are
conserved, with residues belonging to the N-terminal domain
(residues 1–12 and 35–145, OASS-A numbering [47]) showing a
90% identity, residue P67 being substituted by A69 in OASS-B.
The larger divergence is observed in the loop around G228 in the
front of PLP that has been suggested to undergo minor
conformational changes during catalysis [47]. In particular,
substitution Q227RP207 leaves one side of the pocket more
accessible in OASS-B. In addition, as already discussed [19], G230
is substituted by R210, a residue that in some microorganisms
plays a role in the selection of O-phosphoserine as the preferred
substrate of the B isoform [53,109]. The higher conservation
degree of the residues belonging to the N-terminal domain with
respect to those of the C-terminal domain allow the last two
residues of pentapeptides docked in the active sites of OASS-A and
OASS-B to occupy similar positions [19]. In spite of these

OASS-A and OASS-B were expressed and purified as
previously described [19]. The binding affinity of selected ligands
to OASS-A and OASS-B was determined by monitoring the
increase in fluorescence emission of the bound PLP at 500 nm
following excitation at 412 nm [16,55]. Emission spectra were
collected at increasing ligand concentrations in the presence of
0.05–1 mM OASS, 100 mM Hepes buffer, pH 7.0 at 20uC.
DMSO and/or potassium hydroxide were added when needed to
solubilize the compounds and pH was checked to be between 7
and 8.5. Spectra were corrected for the buffer contribution.
Fluorescence measurements were carried out using a FluoroMax-3
fluorometer (HORIBA-Jobin Yvon), equipped with a thermostated cell-holder.
The dependence of fluorescence intensity at 500 nm on ligand
concentration was fitted to a binding isotherm:
I~I0 z
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Figure 4. Compounds selected by SBVS/LBVS-docking procedures for OASS-A and OASS-B.
doi:10.1371/journal.pone.0077558.g004

structural identity [110] between OASS-A from H. influenzae and
from S. typhimurium, and the comparable affinity of the two
enzymes for the H. influenzae SAT C-terminal pentapeptide
(MNLNI), 44 mM and 120 mM, respectively [16,19]. In particular,
the main binding contribution is provided by hydrogen bonds
formed between the peptide Ile carboxylate group and Thr69 and
Thr73 (Thr68 and Thr72 in S. typhimurium), and by hydrophobic
contacts between the PLP cofactor and Phe144 with the Ile side
chain. (Figure 3). Asn at peptide position P4 is hydrogen bonded
with Ser70 (Ser69 in S. typhimurium) and a water molecule and

common features, only OASS-A is able to interact with high
affinity with SAT [55,56].

Ligand-Based Virtual Screening on OASS-A
The structures of OASS-SAT or OASS-C-terminal peptide
complexes from S. typhimurium are not available. Therefore, the
LBVS was performed using the crystallographic structure of the
two last residues of SAT, i.e. Asn266 and Ile267, complexed with
OASS-A from H. influenzae (PDB code 1Y7L [45]) as a template.
This choice is justified by the relatively high sequence (70%) and
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Table 1. List of compounds selected from virtual screening
and tested against OASS-A.

Compound

Specs code

Kd (mM)

1

AO-623/14653116

3.7 6 0.4

2

AK-968/12383180

82 6 18

3

AQ-390/43356434

95 6 10

4

AD-232/25000151

103 6 9

5

AG-690/36829059

218 6 61

6

AK-968/15253078

283 6 19

7

AG-690/11214033

558 6 131

8

AK-968/41922818

732 6 72

9

AG-690/34035030

1300 6 400

10

AG-690/11665608

. 1500

11

AG-664/25040003

. 1500

12

AP-060/40977348

. 1500

doi:10.1371/journal.pone.0077558.t001

The LBVS set was initially composed of 1200 molecules
showing Global Sum scores higher than 1.5. After individual
inspection, molecules with at least one hydrogen bond acceptor
group and a hydrophobic moiety were selected, docked into the
binding site of OASS-A with GOLD, rescored with the HINT
force field and again individually inspected. A HINT score value
of 3000 was chosen as threshold, indicative of an energetically
stable complex [111]. On the basis of: i) the generated
conformations, ii) the interactions with the surrounding residues
and iii) the HINT score value, seven compounds were selected for
purchase and assays (Table 1 and Figures 4–5).

Structure-based Virtual Screening on OASS-A
The structure-based analysis was performed using the OASS-A
structure to generate the template [47]. On the basis of the Global
Sum score, 600 compounds composed the initial SBVS set. These
were inspected and analyzed as previously described. Following
the pharmacophore hypothesis reported for OASS-A [16],
compounds with two hydrogen bond acceptor groups were
preferentially chosen, docked and re-scored with the HINT
algorithm. The five molecules exhibiting higher scores and better
pharmacophore profiles were selected for purchase (Table 1 and
Figure 4–5) and assays.

Structure-based Virtual Screening on OASS-B
A structure-based analysis was also performed to identify
potential ligands of OASS-B, with a template based on the
OASS-B crystal structure [36]. Eleven compounds were identified
as potential binders (Table 2). The chemical structure of the
selected molecules and their orientations in the active site of
OASS-B are reported in Figure 4 and Figure 6. Since the SAT Cterminal peptide does not bind to OASS-B [55,56], and no other
OASS-B ligands are known to date, the LBVS approach was not
performed for OASS-B.

Figure 5. Best HINT scored conformations of the compounds
selected by the SBVS/LBVS-docking procedures for OASS-A.
The images were prepared with PyMOL (The PyMOL Molecular Graphics
System, Version 1.5.0.4 Schrödinger, LLC.)
doi:10.1371/journal.pone.0077558.g005

contributes more than 15% of the total interaction energy [16].
Analyses of the docking models of several pentapeptides and of
some of the corresponding crystallographic structures indicate that
a good OASS-A binder contains two hydrogen bond acceptor
groups, i.e., the side chain of Asn and the carboxylate of Ile, and a
hydrophobic moiety, i.e., the Ile side chain [16].

PLOS ONE | www.plosone.org

Selected OASS-A and OASS-B ligands
The twenty-three compounds selected as above described are
characterized by at least a hydrogen acceptor group, i.e., a
carboxylic group able to bind into the groove containing Asn71
and Thr72 (OASS-A numbering), and a hydrophobic moiety
occupying the hydrophobic cleft lined by PLP, Phe143 and
Thr177. Most of them also contain a second hydrogen acceptor
7
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Table 2. List of compounds selected from virtual screening
and tested against OASS-B.

Compound

Specs code

13

AK-564/25068019

Kd (mM)
3362

14

AI-204/34859016

8106110

15

AP-402/41884919

.1500

16

AG-664/25098006

.1500

17

AH-262/34614012

.1500

18

AC-776/15493018

.1500

19

AE-848/08323031

.1500

20*

AG-690/12134163

n.d.

21

AG-205/34690008

.1500

22

AO-080/42837941

. 1500

23

AK-968/41172226

.1500

*due to the strong emission at 500 nm for excitation at 412 nm, this compound
was assayed at concentrations lower than 100 mM and no binding was
observed.
doi:10.1371/journal.pone.0077558.t002

of 160-320 Da and most possess an aromatic moiety, except for
compounds 1, 12, 13, 15, 17 and 21. Many compounds in the set
have one or two carboxylate groups.
Recently, virtual screening using the natural compounds subset
of the ZINC database identified ten inhibitors of E. histolytica
OASS, two of which possess dissociation constants in the
micromolar and submicromolar range [11]. These inhibitor
molecules are glycosides (gossypin and vitexin), aromatic compounds (pyrrole and pyrimidine derivatives) or polyhydroxylated
compounds. Surprisingly, only three of them contain a carboxylate
group and, of these, only one was found to be a good binder to
OASS. Furthermore, the carboxylate group of these compounds
is, in the reported models, surprisingly bound to a different site
from that occupied by the carboxylate of the amino acid substrate
[52]. The second best ligand is proposed to make hydrogen bonds
with residues of the substrate-binding loop via a ketone carbonyl
group. Similarly, virtual high-throughput screening on M.
tuberculosis OASS-A led to the identification of fluoro- and nitrosubstituted aromatic compounds [67]. The higher affinity compound from this search places a trifluoromethyl substituent in the
binding pocket where the carboxylate of the amino acid substrate
is bound. This compound was shown to be effective in inhibiting
M. tuberculosis growth with a MIC of 7.6 mM. Very recently,
structure-based and rational design approaches have led to the
optimization of a thiazolidine inhibitor of M. tuberculosis OASS-A
with IC50 in the nanomolar range [112].

Determination of the dissociation constant of selected
ligands towards OASS-A and OASS-B
A total of 12 compounds for OASS-A (Table 1) and 11
compounds for OASS-B (Table 2) predicted to be potential ligands
were experimentally tested by determining their dissociation
constants exploiting PLP fluorescence changes as a function of
ligand concentration [55]. The observed increases in coenzyme
fluorescence and the concomitant blue shifts of the peaks upon
ligand binding result from the closure of the active site – thus
altering the coenzyme microenvironment [29,55]. It is important
to point out that the evaluated dissociation constants for these
compounds correspond to their inhibition constants, Ki, because
they occupy the enzyme active site [18,19], and, therefore, are
purely competitive inhibitors [113].

Figure 6. Best HINT scored conformations of the compounds
selected by the LBVS/docking procedures for OASS-B. The
images were prepared with PyMOL (The PyMOL Molecular Graphics
System, Version 1.5.0.4 Schrödinger, LLC.)
doi:10.1371/journal.pone.0077558.g006

group oriented towards Ser69 or Arg99. These features are
consistent with the chemical properties of SAT peptides previously
analyzed [16]. The identified molecules exhibit a molecular weight
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Figure 7. Binding of ligands to StOASS. Panel A. Fluorescence
emission spectra upon excitation at 412 nm (slitex = 6 nm, slitem =
6 nm) of a solution containing 50 nM StOASS-A and increasing
concentrations of Compound 1 in 100 mM Hepes buffer, pH 7.0, at
20uC. Inset: Dependence of the fluorescence emission intensity at
500 nm on the ligand concentration. The line drawn through data
points is the fit to a binding isotherm with Kd = 3.7 6 0.4 mM. Panel B.
Fluorescence emission spectra upon excitation at 412 nm (slitex = 4 nm,
slitem = 4 nm) of a solution containing 1 mM StOASS-B and increasing
concentrations of Compound 13 in 100 mM Hepes buffer, pH 7.0, at 20
uC. Inset: Dependence of the fluorescence emission intensity at 500 nm
on the ligand concentration. The line drawn through data points is the
fit to a binding isotherm with Kd = 33 6 2 mM.
doi:10.1371/journal.pone.0077558.g007

Figure 8. Docking pose of best binders to the two isozymes
placed into the active sites. Panel A: Docking pose of 1 in the
OASS-A binding pocket. Red and green contours identify the hydrogen
bond acceptor and hydrophobic GRID MIFs. Hydrogen bond donor hot
spots have not been shown for clarity. Panel B: Docking pose of
compound 13 in the OASS-B binding pocket. Red and green contours
identify the hydrogen bond acceptor and hydrophobic GRID MIFs.
Hydrogen bond donor hot spots have not been shown for clarity.
doi:10.1371/journal.pone.0077558.g008

Representative fluorimetric titrations at increasing concentrations of 1 are reported for OASS-A (Figure 7a) and at increasing
concentrations of 13 for OASS-B (7b). Four compounds exhibited
Kd for OASS-A equal to or lower than 100 mM, four between
100 mM and 1 mM, and four exhibited a Kd higher than 1.5 mM
(Table 1). Compound 1 shows the lowest dissociation constant for
OASS-A, 3.8 mM. Analysis of the docked model for 1 in the
OASS-A active site predicts that the compound is well positioned
in the pocket and is able to contact Thr72 with one carboxylic
moiety, Arg99 with the second, and to fill the hydrophobic cleft
with its byciclic moiety (Figure 5/1 and Figure 8a). The proper
location of each moiety is also testified by the superposition with
the corresponding GRID MIFs reported in Figure 8a, where both
PLOS ONE | www.plosone.org

carboxylic groups lie in H-bond acceptor regions (red contours),
and the byciclic moiety in a hydrophobic-favorable area (green
contour). Interaction with Arg99 was not predicted for the wt
peptide docked in StOASS-A active site, whereas contacts between
Arg99 and the tyrosine at position P4 were predicted in the docked
pose of MNYDI, the highest affinity peptide for StOASS-A
(Kdiss = 220 nM) [19]. Compound 2 still exhibits a reasonable
affinity towards OASS-A, i.e., Kd = 82 mM, but lacks a stable salt
bridge with Arg99 (Figure 5/2). Compound 3 shows a similar Kd
(95 mM), and in spite of its not perfectly predicted localization in
the binding pocket, it completely fits the pharmacophoric
requirement, with a carboxylic and a sulfonamide group, as well
9
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Table 3. List of compounds tested against both OASS-A and
OASS-B.

Compound

Kd OASS-A (mM)

Kd OASS-B (mM)

1

3.7 6 0.4

50 6 5

2

82 6 18

. 1500

3

95 6 10

. 1500

13

29 6 3

33 6 2

14

. 1500

810 6 110

doi:10.1371/journal.pone.0077558.t003

binding site in a different orientation, as they interact with Asn71,
Thr72 and Gln142, and with Ser69. Compound 9 (Figure 5/9)
was selected from the virtual screening because of the presence of a
carboxylic group and a nearby aromatic hydrophobic ring, and
compound 11 was selected because our docking model suggests
that it is properly located and able to contact both Thr72 and
Ser69 (Figure 5/11). However, neither of them binds to OASS-A
in our assay. Likewise, no binding was observed for 12 (Figure 5/
12), probably due to the presence of the additional hydrophobic
moiety that might prevent complex formation.
Of the 11 molecules predicted to bind to OASS-B (Table 2),
two, 13 and 14, exhibited Kds of 33 6 5 mM and 810 6 110 mM,
respectively. Compound 13 is characterized by its small size, high
hydrophobicity, and the presence of a chlorine that docking
models (Figure 6/13 and Figure 8b) predict as properly located in
the pocket hydrophobic region. The model also shows hydrogen
bonds formed by the ligand carboxylate moieties with residues
Thr272 and Gln140 on one side and Arg210 on the other. A
similar interaction profile is also exhibited by compound 1, the
best OASS-A binder. While models of 13 show that it does not
completely fill the large binding cavity of OASS-B, both hydrogen
bond acceptor groups and the hydrophobic chlorine correspond to
hot spots of the binding pocket, i.e., the red and green GRID
contours, respectively (Figure 8b). Compound 13 is structurally
similar to the cyclopropane-1-carboxylic acids derivatives identified by some of us [18] and displaying high affinity for the A
isozyme from H. influenzae (HiOASS-A). This structure-activity
relationship study showed that trans-2-substituted cyclopropane-1carboxylic acids were better binders than cis-2-substituted
molecules. Docking of (6)-trans-2-[(1E)-prop-1-en-1-yl]cyclopropanecarboxylic acid in the binding site of HiOASS-A revealed that
the hydrophobic pocket of the enzyme was occupied by the
propenyl moiety in a pose similar to the binding pose of 13, with
the chlorine substituent, also placed in trans configuration with
respect to the carboxylic moiety, properly located in the pocket
hydrophobic region. In agreement with the computational results,
a significantly higher Kd value was measured for 14 (Figure 6/14),
which is predicted to interact with Thr72 and Arg210 through its
tetrazole ring, and places the hydrophobic nicotinic ring in front of
Arg99. No binding was detected for any other of the selected
molecules, i.e., 15–23 (Figure 6/15-6/23), possibly because of
their bulkier substituents, or the absence of strong salt bridges with
Arg210.

Figure 9. GRID MIFs calculated for OASS-A and OASS-B. Red,
blue and green contours identify the hydrogen bond acceptor,
hydrogen bond donor and hydrophobic MIFs, respectively, calculated
for OASS-A (pink cartoons) towards OASS-B (cyan cartoons). In Panel B
compounds 1 and 13 are shown in ball and stick.
doi:10.1371/journal.pone.0077558.g009

as an isopropyl hydrophobic moiety (Figure 5/3). Models of
Compound 4 predict that it places both one carboxylic moiety and
a hydrophobic group in the good positions, but the short distance
between the two carboxylic groups does not allow the second to
reach Arg99 (Figure 5/4). Compounds 5 and 6 (Figures 5/5 and
5/6, respectively) are similarly predicted from models to be located
in the binding pocket, contacting both Thr72 and Arg99, but the
second H-bond acceptor moiety, i.e. a nitro group in 5 and a
pyridine nitrogen in 6, appears to be less effective than that of 1. A
slightly different orientation is predicted for 7, whose carboxylic
moiety interacts with both Thr72 and Gln142, while the furan ring
oxygen barely reaches Asn71 (Figure 5/7). Compounds 8 and 10
(Figure 5/8 and 5/10, respectively) – the latter showing significant
less affinity towards the target – are modelled to occupy the

PLOS ONE | www.plosone.org

Ligands for both OASS-A and OASS-B
The common MIFs generated by GRID for OASS-A and
OASS-B are reported in Figure 9A. The similarity of the scaffold
identified for the two OASS isozymes reflects the pharmacophoric
similarity of the two binding sites. Hydrogen bond acceptor and
donor MIFs (red and blue contours, respectively) are nearly
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conserved, with the exception of a small red contour in OASS-B
placed over the PLP, just in front of Arg210 (Ala231 in OASS-A)
(Fig 9A). This observation led us to test the compounds
characterized by the lowest dissociation constants for OASS-A
against OASS-B and vice versa (Table 3). The three compounds
showing dissociation constants lower than 100 mM towards
OASS-A, i.e., 1, 2 and 3, were tested against OASS-B. Only 1
was able to bind OASS-B, with a dissociation constant of 50 mM.
Of the two compounds that bind to OASS-B, i.e., 13 and 14,
compound 13 binds to OASS-A with a dissociation constant of
29 mM, thus exhibiting similar affinity for both isozymes. These
findings deserve notice, due to the previous observation that
peptide ligands [19] always showed a higher affinity for the A
isoform with respect to the B isoform. This was explained as a filter
mechanism that evolved to prevent binding of SAT to OASS-B.
The identification of a ligand specific for the A isoform (1) and a
ligand that binds with good affinity to both isoforms (13) opens the
way to the development of more potent inhibitors of cysteine
biosynthesis in pathogenic bacteria. In particular, 13 has the
properties of a good lead as it is completely unadorned and has
accessible chemistry. In addition, although the presence of a vinyl
halide moiety could in principle confer reactivity towards residues
of the active site, similarly to the chemistry observed, e.g., for cvinyl-GABA [17], no reaction or time-dependent inactivation of
OASS was observed under our experimental conditions.
Our computational/experimental procedure has been quite
successful in identifying OASS inhibitors from a relatively small
library. However, the affinities of compound 1 and 13 are still in
the micromole range. According with the orientation assumed by
the ligands into the model provided by GOLD and, most of all,
with the extension of the MIFs calculated by FLAP, modifications
might be introduced in order to optimize compounds towards the
corresponding target. For instance, in the case of compound 1, the
bicyclo heptene moiety could be extended towards Met119,
Phe143 and Ala231, and functionalized with a H-bond acceptor
group for contacting Gln142 on one side or with a H-bond donor

group on the other side for contacting the PLP phosphate group.
Also in the case of compound 13, a H-bond donor group could be
added to contact the PLP phosphate. Moreover, a more bulkier
substituent bearing a H-bond acceptor moiety like a carboxylate,
could be introduced on carbon 2, to reach Arg99 and form a salt
bridge.

Conclusions
The biological roles of OASS-A and OASS-B in S. typhimurium
virulence and persistence in the host are still unclear despite the
large number of studies dealing with their detailed biochemical
and biological characterization [27,28,35,47,114–116]. The
knowledge of the relative abundance and regulation by effectors
of the two isozymes during infection is a relevant missing
information that can contribute to the pharmacological exploitation of these targets. For example, it has been recently shown that
the activity of OASS-B on thiosulfate could represent an energy
saving path to cysteine biosynthesis and could be preferred in
metabolic conditions where the conservation of ATP and NADPH
is important [117]. In addition, very recently, works by Hayes and
coworkers [118,119], identified OASS as the activating factor for a
toxin that controls contact-dependent growth inhibition in E.coli.
Surprisingly, the interaction between OASS and the toxin exploits
the same mechanism of SAT-OASS complex formation, e.g.
insertion of the C-terminal peptide in the OASS active site. Hence,
OASS is a multifaceted enzyme whose function may indirectly
influence processes such as long-term survival inside the host and
biofilm formation.
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